All Stories

  1. Unexpected cardiac arrest in young adults and athletes: the underappreciated impact of autoimmunity
  2. Circulating anti-Ro/SSA-antibodies and risk of heart rate-corrected QT interval prolongation: a meta-analysis
  3. Inflammation in Atrial Fibrillation–Related Stroke
  4. Anti-Ro/SSA-antibody testing for isolated atrioventricular block in adults: a diagnostic and therapeutic work-up
  5. hERG epitope mimic-decoy peptide corrects autoimmune-long QT syndrome in guinea pigs
  6. Kinase-driven inflammasome resolution: shifting the paradigm for atherosclerosis management
  7. REPLY
  8. Sex Hormone Profiles in Patients With Torsades de Pointes Ventricular Tachycardia
  9. Androgen Replacement Therapy for Torsades de Pointes in Males: Hormonal Modulation as a Novel Antiarrhythmic Strategy
  10. Urinary tract infections caused by Gram-negative bacteria in elderly hospitalized patients: Epidemiology, clinical features and outcomes in the era of antimicrobial resistance
  11. Hepatitis C Virus Opportunistic Screening in South-Eastern Tuscany Residents Admitted to the University Hospital in Siena
  12. Autoimmune cardiac channelopathies and heart rhythm disorders: A contemporary review
  13. Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation
  14. Searching for biomarkers of atrial cardiomyopathy at high risk of cardioembolism: What are the missing pieces of the puzzle?
  15. Impact of Hospitalization on Sarcopenia, NADPH-Oxidase 2, Oxidative Stress, and Low-Grade Endotoxemia in Elderly Patients
  16. Atrial Thrombogenicity and Residual Stroke Risk in Atrial Fibrillation
  17. Pro-arrhythmic potential of proton-pump inhibitors
  18. Rate and predictors of thromboprophylaxis in internal medicine wards: Results from the AURELIO study
  19. Ventricular arrhythmias after atrial fibrillation electrical cardioversion: A multicenter study
  20. Editorial: Case reports in general cardiovascular medicine: 2023
  21. Hydroxychloroquine, Chloroquine, and Arrhythmic Risk in Systemic Autoimmune Diseases: Focus More on the Patient and You Will Keep the Rhythm!
  22. Life-Threatening Arrhythmias in Patients With Takotsubo Syndrome
  23. Increased interleukin‐6 levels are associated with atrioventricular conduction delay in severe COVID‐19 patients
  24. The Impact of Sex and Arterial Stiffness Interactions on the Outcome after an Acute Ischemic Stroke: A Retrospective Cohort Study
  25. Advanced Atrioventricular Block in Athletes: Prevalence and Role of Anti‐Ro/Sjögren Syndrome–Related Antigen A Antibodies
  26. Myocarditis and Arrhythmias
  27. Elevated Interleukin‐6 Levels Are Associated With an Increased Risk of QTc Interval Prolongation in a Large Cohort of US Veterans
  28. Editorial: Year in review: discussions in general cardiovascular medicine
  29. Pathogenic pathways and therapeutic targets of inflammation in heart diseases: A focus on Interleukin‐1
  30. Editorial: Case reports in general cardiovascular medicine: 2022
  31. Editorial: New challenges and future perspectives in autonomic neuroscience
  32. Editorial: Insights in general cardiovascular medicine: 2022
  33. Anti-Ro/SSA Antibodies Blocking Calcium Channels as a Potentially Reversible Cause of Atrioventricular Block in Adults
  34. Fir(e)ing the Rhythm
  35. Reply
  36. Contribution of cytokine-mediated prolongation of QTc interval to the multi-hit theory of Torsade de Pointes
  37. Cryptogenic stroke as a working diagnosis: the need for an early and comprehensive diagnostic work-up
  38. Worldwide survey on implantation of and outcomes for conduction system pacing with His bundle and left bundle branch area pacing leads
  39. Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19‘ by Jain and Sharma
  40. Anti-Ro/SSA-antibodies and heart rhythm disturbances in the general population: the ‘dark side of the immune’
  41. Maternal Anti-Ro/SSA Autoantibodies and Prolonged PR Interval in a Competitive Athlete
  42. Safety of Intravenous Thrombolysis and Mechanical Thrombectomy in Bilateral Posterior Cerebral Artery Territory Infarction
  43. Editorial: Insights in General Cardiovascular Medicine: 2021
  44. Anti-Ca v 1.2 Antibody–Induced Atrioventricular Block as a Novel Form in the Adult: Long-Term Pacemaker-Sparing Activity of Hydroxychloroquine
  45. Markers of Atrial Cardiopathy in Severe Embolic Strokes of Undetermined Source
  46. Editorial: Highlights in General Cardiovascular Medicine: 2021
  47. Interleukin-6 Elevation Is a Key Pathogenic Factor Underlying COVID-19-Associated Heart Rate-Corrected QT Interval Prolongation
  48. P-wave dispersion as a marker of atrial cardiopathy in embolic stroke of undetermined source
  49. Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19
  50. Implantation of cardiac electronic devices in active COVID-19 patients: Results from an international survey
  51. Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases
  52. Off‐Label Use of Hydroxychloroquine in COVID‐19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance
  53. Transient Hypogonadism Is Associated With Heart Rate–Corrected QT Prolongation and Torsades de Pointes Risk During Active Systemic Inflammation in Men
  54. Unravelling Atrioventricular Block Risk in Inflammatory Diseases: Systemic Inflammation Acutely Delays Atrioventricular Conduction via a Cytokine‐Mediated Inhibition of Connexin43 Expression
  55. Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?”
  56. Anti-Ro/SSA Antibodies and the Autoimmune Long-QT Syndrome
  57. Outcome After Acute Ischemic Stroke Treatment During Covid-19 Outbreak in South-East Tuscany
  58. Proton Pump Inhibitors Directly Block hERG-Potassium Channel and Independently Increase the Risk of QTc Prolongation in a Large Cohort of US Veterans
  59. Roxithromycin-Associated Acute Thrombocytopenia
  60. Drug-Associated QTc Prolongation in Geriatric Hospitalized Patients: A Cross-Sectional Study in Internal Medicine
  61. Increased Arterial Stiffness is a Predictor of Delayed Ischaemic Stroke After Subarachnoid Haemorrhage
  62. Risk of QTc Interval Prolongation Associated With Circulating Anti‐Ro/SSA Antibodies Among US Veterans: An Observational Cohort Study
  63. Worldwide Survey of COVID-19 Associated Arrhythmias
  64. Letter by Acampa et al Regarding Article, “Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage in Patients With a History of Migraine”
  65. Neutrophil extracellular traps release in gout and pseudogout depends on the number of crystals regardless of leukocyte count
  66. Antirheumatic agents in covid-19: is IL-6 the right target?
  67. Letter by Lazzerini et al Regarding Article, “Autoantibody Signature in Cardiac Arrest”
  68. IL-6 (Interleukin 6) Blockade and Heart Rate Corrected QT Interval Prolongation in COVID-19
  69. Cardiac Arrest Risk During Acute Infections
  70. Non-stenosing Carotid Atherosclerosis and Arterial Stiffness in Embolic Stroke of Undetermined Source
  71. COVID-19, Arrhythmic Risk, and Inflammation
  72. Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes
  73. A Novel Peptide/Antibody-Based Antiarrhythmic Approach to Long QT Syndrome and Beyond
  74. Commentary: Systemic effects of IL-17 in inflammatory arthritis
  75. Editorial: Cardioimmunology: Inflammation and Immunity in Cardiovascular Disease
  76. Electrocardiographic Predictors of Silent Atrial Fibrillation in Cryptogenic Stroke
  77. P Wave Dispersion and Silent Atrial Fibrillation in Cryptogenic Stroke: The Pathogenic Role of Inflammation
  78. Inflammatory cytokines, life-threatening arrhythmias and premature mortality in chronic inflammatory arthritis: time to focus on
  79. Systemic Inflammation Rapidly Induces Reversible Atrial Electrical Remodeling: The Role of Interleukin‐6–Mediated Changes in Connexin Expression
  80. Autoimmune and inflammatory K+ channelopathies in cardiac arrhythmias: Clinical evidence and molecular mechanisms
  81. Inflammation and Atrial Electrical Remodelling in Patients With Embolic Strokes of Undetermined Source
  82. Autoimmune Calcium Channelopathies and Cardiac Electrical Abnormalities
  83. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies
  84. Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation
  85. Emerging Arrhythmic Risk of Autoimmune and Inflammatory Cardiac Channelopathies
  86. Perioperative stroke and hyperhomocysteinemia: a possible pathogenic link
  87. Atrial Cardiopathy and Sympatho-Vagal Imbalance in Cryptogenic Stroke: Pathogenic Mechanisms and Effects on Electrocardiographic Markers
  88. Increased Arterial Stiffness is Associated with Poor Collaterals in Acute Ischemic Stroke from Large Vessel Occlusion
  89. Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes
  90. Torsades de Pointes in Patients with Polymyalgia Rheumatica
  91. Previous use of Statins and Atrial Electrical Remodeling in Patients with Cryptogenic Stroke
  92. Non-HCV-related cryoglobulinemic vasculitis and parvovirus-B19 infection
  93. Postoperative atrial fibrillation and ischemic stroke: The role of homocysteine
  94. Searching Novel Therapeutic Targets for Scleroderma: P2X7-Receptor Is Up-regulated and Promotes a Fibrogenic Phenotype in Systemic Sclerosis Fibroblasts
  95. Increased arterial stiffness is an independent risk factor for hemorrhagic transformation in ischemic stroke undergoing thrombolysis
  96. Autoimmune cardiac channelopathies: the heart of the matter
  97. How to Identify Patients at Risk of Silent Atrial Fibrillation after Cryptogenic Stroke: Potential Role of P Wave Dispersion
  98. Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes
  99. Autoimmune channelopathies as a novel mechanism in cardiac arrhythmias
  100. Combination Therapy With Ceftriaxone and Lansoprazole, Acquired Long QT Syndrome, and Torsades de Pointes Risk
  101. Assessing QT interval in patients with autoimmune chronic inflammatory diseases: perils and pitfalls
  102. Adenosine receptors expression in cardiac fibroblasts of patients with left ventricular dysfunction due to valvular disease
  103. Letter by Acampa et al Regarding Article, “Underutilization of Ambulatory ECG Monitoring After Stroke and Transient Ischemic Attack: Missed Opportunities for Atrial Fibrillation Detection”
  104. Marked QTc Prolongation and Torsades de pointes in Patients with Chronic Inflammatory Arthritis
  105. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date
  106. To the Editor— Carnitine and ventricular repolarization: a complex link?
  107. Induction of autoimmune response to the extracellular loop of the HERG channel pore induces QTc prolongation in guinea‐pigs
  108. Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad
  109. Inflammation and arrhythmic risk in rheumatoid arthritis
  110. Potassium Channel Block and Novel Autoimmune-Associated Long QT Syndrome
  111. Ischemic Stroke after Heart Transplantation
  112. Arrhythmogenicity of Anti-Ro/SSA Antibodies in Patients With Torsades de Pointes
  113. Isolated atrioventricular block of unknown origin in the adult and autoimmunity: diagnostic and therapeutic considerations exemplified by 3 anti-Ro/SSA–associated cases
  114. The role of P2X7 receptors in tissue fibrosis: a brief review
  115. Pathogenesis of the Novel Autoimmune-Associated Long-QT Syndrome
  116. P wave dispersion in cryptogenic stroke: A risk factor for cardioembolism?
  117. Long QT Syndrome: An Emerging Role for Inflammation and Immunity
  118. Comment on “Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: A multicenter study of 689 patients”
  119. Antiarrhythmic Potential of Anticytokine Therapy in Rheumatoid Arthritis: Tocilizumab Reduces Corrected QT Interval by Controlling Systemic Inflammation
  120. Clinically-relevant cyclosporin and rapamycin concentrations enhance regulatory T cell function to a similar extent but with different mechanisms: An in-vitro study in healthy humans
  121. Isolated atrioventricular block of unknown origin in adults and anti-Ro/SSA antibodies: Clinical evidence, putative mechanisms, and therapeutic implications
  122. Cerebellar haemorrhage, factor XI deficiency and concomitant risk factors: Figure 1.
  123. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation
  124. The purinergic P2×7 receptor is expressed on monocytes in Behçet's disease and is modulated by TNF‐α
  125. Statins as a New Therapeutic Perspective in Myocarditis and Postmyocarditis Dilated Cardiomyopathy
  126. Association between high sensitivity C-reactive protein, heart rate variability and corrected QT interval in patients with chronic inflammatory arthritis
  127. Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells
  128. Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis
  129. Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system
  130. Comment on: Letter to the Editor from Clockaerts and Bierma-Zeinstra
  131. Anti-Ro/SSA-associated corrected QT interval prolongation in adults: The role of antibody level and specificity
  132. The “Invulnerability” of the Adult Conduction System to Anti‐Ro/SSA Antibodies? A Matter of Calcium Channel Expression on the Cardiomyocyte
  133. Statins and the Joint: Multiple Targets for a Global Protection?
  134. Homocysteine and P wave dispersion in patients with heart transplantation
  135. Levels of circulating CXCR4-positive cells are decreased and negatively correlated with risk factors in cardiac transplant recipients
  136. Anti-Ro/SSA Antibodies and Cardiac Arrhythmias in the Adult: Facts and Hypotheses
  137. Homocysteine and Raynaud's phenomenon: A review
  138. Arrhythmogenic effects of anti-Ro/SSA antibodies on the adult heart: More than expected?
  139. Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts
  140. Human rheumatoid synoviocytes express functional P2X7 receptors
  141. Autoantibody-mediated cardiac arrhythmias: mechanisms and clinical implications
  142. Hyperhomocysteinemia: a cardiovascular risk factor in autoimmune diseases?
  143. Comparison of Frequency of Complex Ventricular Arrhythmias in Patients With Positive Versus Negative Anti-Ro/SSA and Connective Tissue Disease
  144. Hyperhomocysteinemia, inflammation and autoimmunity
  145. Psychosine‐induced apoptosis and cytokine activation in immune peripheral cells of Krabbe patients
  146. T Lymphocytes as Targets of Statins: Molecular Mechanisms and Therapeutic Perspectives
  147. Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats
  148. Effects of acute administration of iloprost on the cardiac autonomic nervous system and ventricular repolarisation in patients with systemic sclerosis
  149. Connective tissue diseases and cardiac rhythm disorders: An overview
  150. Cyclosporin and tacrolimus increase plasma levels of adenosine in kidney transplanted patients
  151. Corrected QT interval in anti‐SSA–positive adults with connective tissue disease: Comment on the article by Lazzerini et al
  152. Upregulation of A2A adenosine receptor expression by TNF-α in PBMC of patients with CHF: a regulatory mechanism of inflammation
  153. Simvastatin inhibits T‐cell activation by selectively impairing the function of Ras superfamily GTPases
  154. The effects of age and hyperhomocysteinemia on the redox forms of plasma thiols
  155. Simvastatin reduces MMP-3 level in interleukin 1β stimulated human chondrocyte culture
  156. Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases
  157. Blunted increase in plasma adenosine levels following dipyridamole stress in dilated cardiomyopathy patients
  158. Alteration in the redox state of plasma in heart-transplant patients with moderate hyperhomocysteinemia
  159. Reduction in plasma homocysteine level in patients with rheumatoid arthritis given pulsed glucocorticoid treatment
  160. Changes of peripheral A 2A adenosine receptors in chronic heart failure and cardiac transplantation
  161. Oral low-dose dipyridamole protects from intravenous high-dose dipyridamole-induced ischemia. A stress echocardiographic study
  162. Early and delayed increase in plasma homocysteine levels in heart transplanted patients
  163. Pravastatin treatment-associated reduction in plasma homocysteine in heart-transplanted patients
  164. Cardiac dysautonomia in patients with superior vena cava syndrome due to compression by lung cancer
  165. Photopheresis immunomodulation after heart transplantation
  166. Effects Of Dipyridamole And Adenosine On Vasoactive Peptides Calcitonin Gene‐Related Peptide And Atrial Natriuretic Peptide In Humans: Role Of Sympathetic Activation